Subcommittee rejects option to exempt certain medical practices from BPOL on pass-through revenue
Loading...
Summary
HB 1199 would have let localities opt to exempt some Department of Health Professions–regulated practices (for example, oncology clinics) from BPOL taxation on pass-through revenue and instead tax profit. Proponents argued the current treatment penalizes clinics that front high drug costs; opponents and some members raised uniformity and potential tax-shift concerns. The motion to report failed 3–7.
Delegate Scott introduced HB 1199 as a permissive measure intended to let local governments exempt certain health‑care practices from business license (BPOL) taxation on gross receipts that primarily represent pass-through drug and treatment costs, rather than taxing net profit. "Oncology clinics operate very different from most businesses," the patron said, describing steep pass‑through costs and narrow margins.
Supporters included the Medical Society of Northern Virginia and local oncologists. Dr. Matthew Whitehurst, an oncologist, told the committee his practice spends a large share of revenue repurchasing chemotherapy and that BPOL applied to gross receipts can produce large tax bills unrelated to profit. "If an independent office has to close and all treatment becomes hospital based, that's how cost continues to rise," Dr. Whitehurst said in urging support.
Opponents and several members stressed concerns that creating carve-outs would undermine uniformity in the BPOL base and could shift costs to other taxpayers. The committee debated guardrails and whether the change merely clarifies existing tax regulation; the motion to report HB 1199 failed on a recorded vote of 3–7, and the bill did not advance from the subcommittee.
Next steps: With the committee vote failing, the bill does not move forward this session.
